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Abstract.  The twofold purpose of the study was (a) to 
determine if a  MAP-l-like protein was expressed in 
human prostatic DU  145 cells and (b) to demonstrate 
whether a  novel antimicrotubule drug, estramustine, 
binds the MAP-l-like protein to disrupt microtubules. 
SDS-PAGE and Western blots showed that a  330-kD 
protein was associated with microtubules isolated in an 
assembly buffer containing 10 ~tM taxol and  10 mM 
adenylylimidodiphosphate. After purification to 
homogeneity on an A5m agarose column, the 330-kD 
protein was found to promote 6  S tubulin assembly. 
Turbidimetric  (A350),  SDS-PAGE,  and electron micro- 
scopic studies revealed that micromolar estramustine 
inhibited assembly promoted by the 330-kD protein. 
Similarly, estramustine inhibited binding of the 330- 
kD protein to 6-S microtubules independently stimu- 
lated to assemble with taxol. Immunofluorescent 
studies with 13-tubulin antibody (27B)  and MAP-1 anti- 
body (MI-AI) revealed that 60 lxM estramustine (a) 
caused disassembly of MAP-1  microtubules in DU  145 
cells and (b)  removed MAP-I  from the surfaces of 
microtubules stabilized with 0.1  IxM taxol. Taken to- 
gether the data suggested that estramustine binds to a 
330-kD MAP-l-like protein to disrupt microtubules in 
tumor cells. 
T 
HE functional role of microtubule-associated proteins 
is poorly understood. Based on in vitro studies it has 
been proposed that MAPs might regulate microtubule 
assembly and disassembly in cells. Different classes of MAPs 
have been identified suggesting that different MAPs might 
provide for specialized functions associated with subclasses 
of microtubules (Vallee et al.,  1986).  In this regard immu- 
nofluorescent and immunoblotting studies of certain MAPs 
(tau,  MAP-l,  MAP-2,  the 210-215  kD tumor cell MAPs) 
have  shown organ,  tissue,  and cell  specificity (Binder et 
al.,  1986;  Drubin et al.,  1986;  Matus and Riederer,  1986; 
Olmsted et al.,  1986;  Bloom et al.,  1986;  Wiche et al., 
1986). 
Two of the most well-characterized MAPs are the high 
molecular mass  MAPs  1 and 2.  With  several  exceptions 
(Weatherbee et al., 1982; Wiche et al., 1984),  immunologi- 
cal studies have revealed that MAP-2 is almost exclusively 
found in neuronal tissue (Vallee,  1982; Caceres et al., 1984) 
or in cells thought to be derived from the neural crest (Stearns 
and Binder, 1987). By comparison, MAP-1 is found in neu- 
ronal tissue (Vallee et al.,  1986;  Bloom et al.,  1984a,b,c) 
and in a number of mammalian cells as well (Bloom et al., 
1984a;  Vallee et al.,  1986; Wiche et al.,  1984; Asai et al., 
1985;  Sato et al.,  1983).  Lewis et al.  (1986a,b)  have con- 
firmed these results using specific cDNA probes for MAP-2 
and MAP-I.  They found that MAP-2  was exclusively ex- 
pressed in neuronal tissue whereas MAP-1 was expressed in 
a wide variety of cells and tissues. 
In the studies of cultured cells,  MAP-1 was  not always 
found associated with microtubules,  raising doubts  as  to 
whether it represented an authentic MAP in situ. Bloom et 
al. (1984a) and Wiche et al. (1984) found MAP-1 associated 
with interphase microtubules in several mammalian cells. In 
contrast, Sato et al. (1983) and Asai et al. (1985) found that 
MAP-1 antibodies did  not label  microtubules but instead 
stained intranuclear spots, centrosomes (Sato et al.,  1983), 
and stress fibers (Asai et al., 1985).  Clearly, further studies 
are needed to assess the subcellular distributions and proper- 
ties of MAP-1 in nonneuronal cell systems. 
In our studies of the distribution and related functional 
roles of MAPs and microtubules, we have used monoclonal 
antibodies specific for MAP-1 and -2. We have also attempted 
to  identify a  class of drugs which  binds  MAPs,  disrupts 
microtubules, and inhibits the activities of MAPs in vivo. 
Initial studies have revealed that a  novel anti-microtubule 
compound, estramustine, produces microtubule disassem- 
bly in situ (Stearns and Tew, 1985;  Stearns et al.,  1985). 
Likewise, an analogue of estramustine, estramustine phos- 
phate, was found to inhibit brain microtubule assembly in 
vitro (Kanje et al.,  1985; Wallin et al.,  1985) as a result of 
its binding affinity for MAP-2 and tau proteins (Friden et al., 
1987).  Recently, we showed that estramustine-bound brain 
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crotubule disassembly in vitro (Stearns and Tew,  1988). 
In this study, we report the characterization of a "MAP-l- 
like" protein found in DU 145 human prostatic tumor cells. 
The purified protein promoted microtubule assembly in vitro 
and immunofluorescence studies showed that it was associ- 
ated with microtubules in nondividing cells.  Estramustine 
was found to bind purified MAP-1 and inhibit its associations 
with microtubules in vitro and in situ. The data demonstrate 
that estramustine is an anti-MAPs drug that can be used to 
study the role of MAPs in situ. 
Materials and Methods 
Microtubule Protein Purifications 
DU 145 cells (passage 9) were grown to confluency in 60 150-ram 2 dishes 
using DME supplemented with 10% FCS. The cells were dissociated from 
the dishes with 0.08 M sodium citrate in PBS for 20-30 min and harvested 
by centrifugation at 5,000  rpm for 5 min. The cells ('~4 g) were washed 
by centrifugation with 3  changes of PBS and resuspended in  10  ml of 
microtubule stabilization buffer (MSB) j at 4°C after the final wash. MSB 
consisted of 0.1  M  Pipes, 5  mM MgCI2,  5 mM EGTA, 0.1%  aprotinin, 
0.1% PMSF, 0.1% leupeptin, and 0.1% soybean trypsin inhibitor, pH 7.2. 
The mixture was homogenized  with 20 up and down strokes in a 10-ml teflon 
to glass homogenizer (Wheaton Instruments Div., Millville, NJ) at 4°C and 
immediately centrifuged at 39,000  g  for 30 min in a rotor (model SS34; 
Beckman Instruments Inc., Palo Alto, CA). The supernatant was removed 
with a pipette and 10 mM adenylimidodiphosphate  (AMP-PNP) and 1.0 mM 
GTP added and the mixture incubated for 45 min at 37°C (step 1). The mix- 
ture was centrifuged at 39,000 g for 60 min to obtain a microtubule pellet 
(step 2). The pellet was resuspended in 5 ml MSB plus AMP-PNP and GTP 
at 4°C for 45 min, and recentrifuged at 39,000 g for 30 min (step 3). The 
superuatant was removed and steps 1-3 repeated to yield a partially purified 
microtubule mixture. 
For purification of the MAPs,  10  ~tM taxol (Schiff et al.,  1979)  was 
added to the above microtubule mixture for 30 min. The mixture was made 
0.2 M NaCI, vortexed at a setting of 6 for 1 min, and centrifuged at 55,000 
rpm for 1 h in a swinging bucket rotor (model Ti 65; Beckman Instruments 
Inc.; step 4). At this step the samples were layered on a 1-ml cushion of MSB 
containing I5% sucrose, 10 mM AMP-PNP, and 10 [tM taxol. The m'icrotu- 
bule pellet ('~0.3 g) was resuspended in 2 ml MSB containing I0 mM AMP- 
PNP,  10 l.tM taxol, and 0.2 M NaCI (step 5) and step 4 repeated. Steps 4 
and  5  were  repeated  once  more  and  the  final  microtubule  pellet  was 
resuspended in 1 ml MSB at 220C  containing 10 ~tM taxol, 0.4 M NaCI, 
and  10  mM  ATP. The  mixture was homogenized with 2  up-and-down 
strokes of a 5-ml homogenizer (teflon to glass; Wheaton Instruments Div.), 
and after 10 min centrifuged at  100,000 g  for 1 h  in a centrifuge (model 
TL100; Beckman Instruments Inc.). The supernatant containing the MAPs 
protein ("~0.35 mg) was removed with a pipette and chromatographed with 
PBS on a 30 ×  1.5-cm agarose column (A5m; Bio-Rad Laboratories, Cam- 
bridge, MA). The 330-kD protein ("~0.12 mg) was eluted in 1-ml vol in frac- 
tions 24-29 and was found as a pure protein in fractions 24-26.  Tubulin 
(6 S) was purified from 3× cycled microtubule proteins prepared according 
to standard methods of Murphy and Borisy (1975) and using phosphocellu- 
lose PC-11 (Whatman Inc., Clifton, N J) chromatography (Weingarten et al., 
1975). The protein concentration was determined using a kit from Bio-Rad 
by modified methods of  Bradford (1976) and the protein aliquoted and frozen 
at  -80°C. Samples were denatured for SDS-PAGE after the protocols of 
Laemmli (1970).  For SDS-UREA-PAGE, 6  M  urea was included in the 
denaturation buffer, the running buffer, and the gel. Proteins were subjected 
to electrophoresis on 8% acrylamide gels with a 4% stacking gel using a 
40-mA current for 5-8 h.  The purified 330-kD protein was subjected to 
electrophoresis on a 4-12% acrylamide gradient gel to assess purity.  Gels 
were silver stained using a Bio-Rad kit and protocols of Morrissey (1981). 
Western blots were carried out by methods of Towbin et al. (1979)  using 
MAP-1  antibodies (MI-AI), MAP-2 antibodies (AP-9,  -13, and -14),  and 
tubulin antibodies (27B) raised against bovine brain protein in the laboratory 
of Dr.  Lionel Rebhun (University of Virginia, Charlottesville, Virginia). 
1. Abbreviations used in this paper: AMP-PNP, adenylimidodiphosphate; 
MSB, microtubule stabilization buffer. 
Microtubule Assembly Studies 
Microtubule assembly studies were carried out using 6-S tubulin and the 
A5m  column-purified  330-kD  protein.  The  proteins were  thawed  and 
diluted to the appropriate concentrations in MSB containing 1 mM GTP and 
protease inhibitors (see above). Samples at 4°C were mixed together and 
put in cuvettes at 4°C before transferring to a DU7 spectrophotometer pre- 
wanned to 37°C. 
Electron Microscopy 
Microtubules were centrifuged at 90,000 g for 2 h at 23°C to form a pellet 
and the pellet was fixed with 2% gluteraldehyde plus 0.1% tannic acid in 
0.1 M cacodylate buffer for 15 min, washed 3 times with PBS, dehydrated 
with a graded series of ethanol (10-100%), and embedded, stained, and thin 
sectioned according to methods described by Stearns and Brown (1981). 
Sections were sputter coated with a thin layer of carbon using an evaporator 
(Denton Vacuum Inc., Cherry Hill, NJ) and examined in a Phillips 410 mi- 
croscope. 
lmmunofluorescence Studies 
DU 145 cells were cultured in DME containing 10%  FCS using standard 
procedures (Ochs and Stearns, 1981). In brief, cells were allowed to attach 
on carbon-coated, glow-discharged glass coverslips or to  carbon  form- 
var-coated gold grids (200 mesh) for 1-2 d, cells were washed briefly in 
MSB for 1 min at 37 °C and immersed in MSB containing 1% paraformalde- 
hyde, 0.25 % gluteraldehyde, 0.5 % Triton X-100 for 4 min at 37°C. The fixed 
cytoskeletons were  labeled  by  indirect  immunofluorescence using  IgG 
monoclonal antibodies specific for MAP-I, tubulin, and vimentin. Dilutions 
were prepared in PBS with 10% normal goat serum. The MAP-I (MI-AI) 
antibody was used at a  dilution of 1:200,  the tubulin used at  1:100, and 
vimentin antibodies (Boehringer-Mannheim Biochemicals, Indianapolis, 
IN)  used at a  dilution of 1:4.  Secondary antibodies made in  rabbits,  a 
rhodamine-conjugated anti-mouse IgG, and a fluorescein-conjugated anti- 
mouse IgG (Miles Scientific Div., Naperville, IL), were used at dilutions 
of 1:400. Cells were washed in three changes of PBS at pH 7.2  for im- 
munolabeling by methods previously described (Ochs and Stearns, 1981). 
Double labeling studies were carried out using a modified antibody sand- 
wich blocking technique of Kristofferson  et al. (1986). After incubation with 
the first set of primary and secondary antibodies, cells were incubated with 
goat anti-rabbit IgG (Miles Scientific Div.) followed by rabbit anti-goat 
IgG. These incubations were followed by incubations with the second batch 
of  primary and secondary antibodies. Control studies were carried out using 
preabsorbed primary antibody or secondary antibodies. The double label- 
ing studies were also repeated using a polyclonal antitubulin IgG made in 
rabbits (courtesy of Janssen Pharmaceutica, Beerse, Belgium). 
Studies of  Permeabilized  D U 145 Cells 
DU 145 cells cultured on coverslips were gently lysed with 0.001% digitonin 
in MSB and incubated with 0.1 laM taxol for 20 min followed by solutions 
containing afffinity-purified MAP-1 (MI-AI) and FITC-IgG-conjugated sec- 
ondary antibodies at 0.1 lag/ml according to methods of Stearns and Ochs 
(1982).  Cells were then exposed to different reagents (estramustine, es- 
tradiol, nor-nitrogen mustard) and fixed with 1% paraformaldehyde, 0.25% 
gluteraldehyde solutions in MSB for 5 min. The cells were washed with 
PBS, photographed, and stained with tubulin antibodies and RITC-IgG anti- 
bodies before rephotographing. Cells were examined by phase-contrast mi- 
croscopy or epifluorescent microscopy using a 63 x  planapochromatic lens 
and Zeiss optics. 
Drug 
Estramustine was synthesized by A. B. ~  (Helsingborg, Sweden). The 
drug was stored at 4°C in the dark in benzene/ethanol (9:1). Just before use 
the benzene/ethanol was evaporated in a stream of nitrogen in a fume hood 
and the chemical purity of the drug determined by HPLC analysis. The drug 
was redissolved at 1 mg/ml in absolute ethanol, 10 ~tl of which was injected 
onto a 250 × 4.6-mm Cyano Spheri-5 column (Brownlee Labs, Santa Clara, 
CA). The mobile phase was heptane/isopropanol (92.5:7.5)  at a flow rate 
of 1.5 ml/min, attenuation of 100 mAu, and detection wavelength of A230. 
HPLC analysis of the estramustine indicated it was >99% pure. HPLC 
also showed that solubilization in dimethylsulfoxide and aliquoting into a 
microtubule stabilizing buffer did not result in breakdown products after 
several hours indicating the drug was stable under these conditions. 
The Journal  of Cell Biology,  Volume  107, 1988  2648 Results 
Double immunofluorescent studies with MAP-1 antibody re- 
vealed that a MAP-l-like protein colocalized with the inter- 
phase microtubules in DU 145 cells (Fig. l, a and b). Double 
labeling with vimentin, tubulin, and MAP-1 antibodies indi- 
cated that microtubules and vimentin filaments often closely 
overlapped in the perinuclear region (Fig.  1, c and d) and 
that MAP-1  might possibly interact with both types of fila- 
ments (Fig.  l, e and f). Note that the MAP-1 patterns often 
ranged between the two extremes shown in Figs.  1, b and d, 
depending on the individual cell examined. Usually the fre- 
quency of coincident fiber staining by the three antibodies 
was  ~80 percent and the remaining cells were too poorly 
stained to discern if discrete fiber patterns existed (see Fig. 
1, e and  f). MAP-2 antibodies raised against distinct epitopes 
(AP14, AP9, and AP13) failed to even faintly stain DU 145 
cells (data not shown). Single antibody labeling studies con- 
sistently supported the double labeling data, ruling out possi- 
ble errors arising for antibody binding nonspecifically in the 
studies.  Also, background fluorescence from the aldehyde 
fixatives was minimal. 
For further characterization of the MAP-l-like protein, the 
microtubules were partially purified from crude extracts of 
DU 145 cells. SDS-UREA-PAGE revealed that the isolated 
microtubule preparations contained tubulin, and a 330-kD 
protein plus numerous other proteins (Fig. 2). Western blots 
showed that MAP-1  antibodies raised against  mammalian 
brain antigen (MI-AI) specifically bind the 330-kD protein 
(Fig.  3).  MAP-2 antibodies raised against distinct MAP-2 
epitopes (AP9, AP13, and AP14) did not bind any of the pro- 
teins.  Comparative  blots  of  bovine  brain  microtubules 
showed that MAP-1 antibody binds a 330 kD brain protein 
and that MAP-2 binds a 300-kD peptide indicating the anti- 
bodies were specific for their respective peptides (data not 
shown). Taken together the data indicate that a MAP-l-like 
protein is expressed in DU  145 cells. In contrast, MAP-2 
does not appear to be expressed in DU 145 cells, since the 
particular MAP-2  antibodies  used  failed to detect an  im- 
munoreactive protein. 
The 330-kD protein was purified for two purposes: (a) to 
characterize its ability to promote 6-S tubulin assembly and 
(b) to determine if estramustine can bind and inhibit its as- 
sembly promoting activities in vitro. Microtubules were iso- 
lated in an assembly buffer that contained 10 mM AMP-PNP, 
since addition of AMP-PNP to the buffer (as opposed to 
ATP) increased the amounts of the 330-kD protein present 
by an order of magnitude.  During subsequent purification 
steps, the microtubules were assembled and stabilized with 
10 ~tM taxol for 20 min before adding 10 mM AMP-PNP to 
the buffer. The microtubules were then centrifuged through 
a 15 % sucrose cushion (three times) to obtain a microtubule 
fraction which consisted largely of tubulin and a prominent 
330-kD protein (Fig. 2, lane/). Densitometric scans at 550 
nm showed that the 330-kD protein represented "~10% of the 
total protein associated with the isolated microtubules. The 
MAPs were separated from the microtubules by resuspend- 
ing the microtubules in buffer containing 10 IxM taxol,  10 
mM ATP, 0.4 M KCI, and 0.01% DTT. After centrifugation 
through  a  15%  sucrose  gradient  the  microtubules  were 
pelleted leaving the MAPs in the supernatant (Fig. 2, lane 
2). When the MAPs were eluted on an A5m agarose column, 
the  330-kD  protein eluted as  a  pure protein in  fractions 
24-28  (Fig.  3).  Silver-stained  gels  revealed  very faint 
(diffuse) low molecular mass bands in these fractions. West- 
ern blots confirmed that the purified 330-kD peptide was 
MAP-1 and showed that MAP-2 could not be detected in the 
preparations (Fig. 3). The 330-kD protein usually migrated 
as a single band, although it may turn out to be a dimer (see 
Fig.  2). 
Microtubule Assembly Studies: Inhibitory 
Effects of  Estramustine 
Turbidimetric (A35o) analysis revealed that the 330-kD pro- 
rein stimulated assembly of 6-S tubulin purified from DU 
145 cells (Fig. 4). The freshly purified 330-kD peptide (0.2 
mg/ml) was mixed with 6-S tubulin (2 mg/ml) at 4°C and the 
mixture was allowed to warm to 37°C in the spectrophotome- 
ter. If0.1 pM taxol was included in the mixture, an initial in- 
crease in turbidity occurred by 2 min and equilibrium was 
reached after "o7 min. In the other samples an increase in tur- 
bidity  was  recorded  after  ,~7  min  and  equilibrium  was 
reached by "~17 min. The addition of increasing amounts of 
estramustine  (20-60  gM)  to  the  mixture  (at  time  zero) 
significantly diminished the rate of increase in turbidity and 
the final equilibrium reached in a  dose-dependent manner. 
The turbidity at equilibrium was "ol/2 the maximum in sam- 
ples containing 20 IxM drug and near zero in samples con- 
mining 60 ~tM estramustine. By comparison, the addition of 
60 I~M estradiol plus 60 IxM nor-nitrogen mustard to the pro- 
tein mixtures did not affect the rate of change in turbidity or 
greatly diminish the  final  equilibrium achieved.  The tur- 
bidity of tubulin (2 mg/ml) alone changed very little with or 
without the addition of 60 ~tM estramustine. 
When 60 IxM estramustine was added to a preparation at 
equilibrium, a dramatic decrease in turbidity was recorded 
over '~7 min. Reduced levels of 20 and 30 IxM estramustine 
partially reduced the turbidity observed at equilibrium (data 
not  shown).  In  contrast,  when  60  ~tM  estramustine  was 
added to the taxol-stabilized microtubules it produced only 
a  small decrease in turbidity after '~5 rain, indicating the 
taxol microtubules were resistant to the drug effects. After 
centrifugation  of  these  microtubules,  SDS-UREA-PAGE 
showed that 60 ~tM estramustine had removed the 330-kD 
protein  from  the  taxol-microtubules  that  accumulated  in 
the pellets. Whereas in the absence of drug treatment, the 
330-kD protein was associated with the microtubule pellet 
(Fig. 5). 
Electron Microscopic Studies 
The effects of estramustine on microtubule assembly were 
further examined by thin section electron microscopy. Fig. 6, 
a and c shows that microtubules made from the purified 330- 
kD protein and 6-S tubulin were coated with numerous fila- 
ments (arrowheads) which sometimes cross-linked adjacent 
microtubules. If these microtubules were stabilized with 0.1 
I  JaM taxol and then exposed to 60 lxM estramustine for 20 min 
before fixation (and centrifugation),  the  microtubule sur- 
faces were smooth in appearance (Fig. 6, b and d), indicating 
estramustine had removed the 330-kD protein from the mi- 
crotubule surfaces. In agreement with these results, 60 ~tM 
estramustine almost completely inhibited microtubule for- 
mation (except for the occasional microtubule) when a mix- 
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beled with antibodies  raised against 
tubulin, MAP-l,  and  vimentin. (a 
and b) Tubulin, MAP-l; (c and d) 
vimentin, MAP-I; (e and  f) vimentin, 
tubulin. Demonstrates  that  MAP-I 
and tubulin  exhibit identical patterns; 
that  vimentin filaments  colocalize 
with MAP-1 and tubulin in the peri- 
nuclear region.  Bar,  10 ~tm. 
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PAGE (8% gel) of microtubule pro- 
teins partially purified from DU 145 
cells. (Lane 1) Isolated microtubule 
fraction; (lane 2) the 330-kD MAPs 
(arrowhead) removed with salt and 
ATP  from  the  taxol  microtubules. 
Numbers on the side indicate the mo- 
lecular masses in kilodaltons. 
Figure 3. (Lane  1) Amido black- 
stained nitrocellulose strip con- 
raining the  330-kD protein  (3 
I.tg). Western blots with (lane 2) 
MAP-1 and (lane 3) MAP-2 an- 
tibodies. 
ture of the 330-kD (0.2 mg/ml) protein and 6-S tubulin (2 
mg/ml) were incubated under assembly conditions in the ab- 
sence of taxol. Instead numerous electron-dense aggregates 
formed as a result of drug treatment. Protofilaments or pro- 
filament ribbons of partially formed microtubules were not 
found in any of the preparations (Fig.  6 e). 
In Situ Effects of  Estramustine 
The effects of estamustine on microtubules were examined 
in intact and in digitonin permeabilized (i.e., partially lyzed) 
DU 145 cells. Fig. 7, a-f shows cells fixed and stained with 
tubulin antibody (T/B) and MAP-1  antibody (MI-AI) after 
exposure to 60 ~tM estramustine for 5, 30, and 50 min. After 
5-min exposure the microtubules were partially disassem- 
bled, apparently from their distal ends (Fig. 7, a and b). Af- 
ter 20 min, the only microtubules remaining were found at 
the cell center surrounding the perinuclear region (Fig. 7, c 
and  d),  and  after 50  min exposure to  drug,  virtually no 
microtubules remained intact (Fig. 7, e and f). MAP-1  was 
found on the microtubules at all stages of their disassembly. 
However, at 50 min MAP-1 antibody labeled perinuclear fila- 
ments that remained behind after complete removal of the 
microtubules (Fig. 7 f). Exposure of the cells to high drug 
levels (120 ~tM estramustine for 50 min) failed to destroy 
these structures or to remove the MAP-1  antigen from their 
surface  (Fig.  8,  a  and  b).  Double  labeling  studies  with 
vimentin antibodies and MAP-1 antibodies showed that after 
complete disassembly of the microtubules, the MAP-1 anti- 
gen was bound to clumps of intermediate filaments (Fig. 8, 
a  and b).  Control studies using 60 IxM estradiol and nor- 
nitrogen mustard failed to produce microtubule disassembly 
or disrupt the distribution of the 330-kD antigen (i.e., dis- 
place MAP-1  from the microtubule's surface). 
As  an  alternate  approach,  we  used  unfixed,  digitonin- 
permeabilized cells to test the effects of estramustine on the 
"taxol-stabilized" microtubules in cells. After permeabiliza- 
tion the microtubules were stabilized with 0.1  lxM taxol for 
20 min at 37°C. Immunofluorescent labeling with MAP-1 an- 
tibody  and  goat  anti-mouse  secondary  antibodies  (IgG- 
FITC) for 30 min at 37°C revealed that the 330-kD protein 
was  associated  with  microtubules  before  drug  treatment 
(Fig. 9 a). The cell was photographed for 10 s and then ex- 
posed to 60 I~M estramustine for 30 min at 37°C before being 
rephotographed. The immunofluorescent image in Fig. 9 b 
revealed that estramustine treatment had removed most of 
the MAP-1  antibody IgG-FITC fluorescent signal from the 
microtubule surfaces.  Some filamentous labeling was still 
observed in the perinuclear zone. After fixation, and relabel- 
ing  with  fresh  MAP-1  antibody  (and  secondary antibody 
coupled to FITC) it was clear that the microtubules were in- 
deed barren of any MAP-l,  indicating the 330-kD protein 
was removed in response to estramustine. Subsequent label- 
ing with  tubulin  antibody (T/B) confirmed that the taxol- 
Steams et al.  Estramustine  Binds  a  MAP-l-like  Protein  2651 Figure 4. Turbidimetric (A350) analysis of 6-S tubulin assembly. All the mixtures contained the 330-kD protein (0.2 mg/ml) and 6-S tubu- 
lin (2 mg/ml). The cuvettes contained (,) protein only or protein plus:  (X) 0.1  IxM taxol; (a) 60 ~tM estradiol and 60 ~tM nor-nitrogen 
mustard; (o) 60 laM estramustine;  (*) 30 p.M estramustine;  (e) 20 ~tM estramustine; (<~) 2 mg/ml tubulin only; (I) 2 mg/ml tubulin only 
plus 60 ~tM estramustine. The arrows indicate when 60 p.M estramustine was added to the cuvettes containing protein only (O) or protein 
plus taxol (X). (Inset) Silver-stained SDS-PAGE of the purified tubulin (lane 1) and MAP-I (lane 2) used. 
Figure 5.  Silver-stained  SDS-PAGE 
(8%  gel) of taxol microtubules  pel- 
leted in the absence (lane 1 ) and in 
the presence (lane 3) of 60 IxM es- 
tramustine. Lane 2 shows the super- 
natant from the preparation  in lane 
3.  Numbers  indicate  the  molecular 
masses in kilodaltons. 
stabilized  microtubules  had  remained  intact  during  the 
course of drug treatment (Fig. 9 c).  Prolonged exposure to 
drug for 50 min did not reduce the extent of MAP-1 antibody 
staining in the perinuclear zone. 
Photobleaching did not account for the reduction in MAP- 
1 antibody staining as the exposure times were limited to 10 s 
and  relabeling  with  MAP-1  antibody  did  not enhance  the 
MAP-1  signal. In control experiments with 60 ~tM estradiol 
and nor-nitrogen mustard the MAP-1 antibody staining was 
not reduced and the photographic exposure times used failed 
to bleach the signal (data not shown). Stereo high voltage im- 
munogold electron microscopic studies of whole mount DU 
145  cells  supported  the  immunofluorescent  observations 
reported in Fig.  9  (data not shown). 
Discussion 
In this paper, we have shown that a 330-kD MAP-l-like pro- 
tein is present in DU 145 cells. Preliminary immunofluores- 
cence studies and Western blot analysis with MAP-1A and 
MAP-1B monoclonal antibodies raised against brain antigens 
(courtesy  of George Bloom,  University  of Texas,  Dallas; 
Bloom et al.,  1984a,b,c) have revealed that the 330-kD pro- 
tein identified in DU 145 cells is probably MAP-1A (data not 
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stabilized 6-S-microtubules incubated with 0.2 mg/ml MAP-1 and 
60 BM estramustine for 20 min at 37°C (b and d); and of the ag- 
gregates formed when MAP-I and 6-S tubulin were incubated under 
assembly conditions in the continual presence of 60 IxM estra- 
mustine (e). The longitudinal (a and b) and cross section views (c 
and d) demonstrated that MAP-I decorated the microtubule sur- 
faces in the absence of drug (a and c, arrowheads)  but not in the 
presence of drug (b and d). Bars, 0.1  wn. 
shown). The 330-kD protein was found to coassemble with 
isolated microtubules and to promote 6-S tubulin assembly, 
indicating it acts like a true MAP in vitro and in situ. The 
properties of the 330-kD protein were examined with respect 
to the binding properties of a novel anti-microtubule drug, 
estramustine. Micromolar levels of estramustine were found 
to inhibit the assembly-promoting activities of the 330-kD 
protein and to produce disassembly of the microtubules as- 
sembled in the presence of this protein.  Estramustine was 
partially effective at 20 IxM levels and completely effective 
at 60 I.tM levels. 
The apparent high levels of estramustine required for inhi- 
bition  of  MAP-1  binding  to  tubulin  under  physiological 
buffer conditions might arise from (a) limited drug solubility 
and binding efficiency under physiological conditions,  (b) 
the kinetic effects of microtubule assembly-disassembly on 
drug binding, and (c) tubulin competition with estramustine 
for MAP-1  sites. With respect to the latter point, as much as 
1/2 of the 330-kD molecule may associate with the microtu- 
bule surface (see Amos, 1977). Thus, accessibility of crucial 
segments of the MAP-1  molecule, the environmental effects 
and competitive binding by tubulin could drastically affect 
binding parameters. 
Convincing evidence that estramustine functioned as an 
anti-MAP drug in situ was derived from immunofluorescent 
(and immunogold) labeling studies of DU 145 cells. Under 
conditions  where  taxol-stabilized  microtubules  were  ex- 
posed to estramustine, the 330-kD protein was removed from 
the microtubule surfaces. This was a direct result of drug ac- 
tion related to unique properties of the synthetic compound 
(i.e., probably the carbamate-ester bond that links estradiol 
to nor-nitrogen mustard; Tew and Stearns,  1988), since the 
drug constituents, estradiol and nor-nitrogen mustard,  did 
not bind the 330-kD protein or tubulin. The in situ observa- 
tions were strongly supported by SDS-PAGE, turbidimetric, 
and  electron microscopic studies of isolated microtubules 
which confirmed that estramustine had indeed removed the 
330-kD protein from the surfaces of the taxol microtubules. 
We interpret the data in this manner for two reasons. Firstly, 
the "taxol-microtubules" appeared smooth after drug treat- 
ment in vitro or were no longer labeled with MAP-I antibody 
in situ. Secondly, the drug prevented assembly of any inter- 
mediate forms of microtubules (i.e., rings or protofilamen- 
tous  sheets).  These intermediates would probably require 
specific MAP-tubulin binding at the concentrations of pro- 
tein used. Thus, the electron-dense aggregates induced by es- 
tramustine were probably formed from MAP-1  drug com- 
plexes.  Interestingly, this may mean that estramustine can 
form crystalline arrays in association with MAP-l, perhaps 
not dissimilar from vincristine-tubulin lattices. 
In studies of intact cells we have previously reported that 
estramustine  or  dansylated  estramustine  (Stearns  et  al., 
1985; Stearns and Tew, 1985; Stearns and Wang,  1987; Wang 
et al., 1987) diffused in and interfered with microtubules and 
normal cellular functions. For example, at reduced concen- 
trations of ,,o 30 BM, the drug inhibited intracellular trans- 
port (Steams and Tew,  1985; Steams and Wang,  1987) and 
partially reduced the population of microtubules.  That is, 
partial disassembly of the microtubules was observed at the 
distal  regions of the  microtubules.  Higher drug  levels of 
60-120 IxM produced a  rapid disassembly of the microtu- 
bules and a concomitant disruption of other cytomatrix com- 
ponents (Stearns et al.,  1985; Wang et al.,  1987). The cells 
stopped dividing and eventually died even at reduced levels 
of  10  lxM  estramustine  (Stearns  et  al.,  1985).  The data 
presented  here  indicated  that  the  principal  target  of es- 
tramustine in DU 145 cells is MAP-1 and that the manifested 
effects of estramustine on microtubules were a result of drug 
binding to the 330-kD protein. We cannot rule out the possi- 
bility that other MAPs present in DU  145 cells also might 
bind the drug.  Several reports have shown that MAPs with 
molecular masses of 200-220-kD are present in cultured cell 
lines,  including  HeLa  cells  (Bulinski  and  Borisy,  1980; 
Weatherbee et al., 1980; Debrabander et al., 1981) and neu- 
roblastoma cells (Olmsted and Lyon, 1981). Also, a 190-kD 
polypeptide has been found associated with microtubules of 
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tures  of  DU  145  double  labeled 
with  antibodies after  exposure  to 
60 lxM estramustine for (a and b) 
5,  (c and d) 30, and (e and f)  50 
min. The cells were  labeled with 
(a, c, and e) tubulin, and (b, d, and 
f) MAP-1 antibodies. Some MAP-I 
was associated with vimentin fila- 
ments at 50 min (see Fig. 8). Bar, 
10 ~tm. 
The Journal of Cell Biology, Volume 107, 1988  2654 Figure 8.  Immunofluorescence pictures of a DU 145 cell exposed 
to  120 ~tM estramustine  for 50 min and double labeled with (a) 
MAP-1 and (b) vimentin antibodies.  Bar, 10 p.m. 
Figure 9.  Immunofluorescence images demonstrating the effect of 
estramustine  on MAP-I's distribution  in DU 145 cells lysed with 
digitonin in MSB containing 0.1  ~Vl taxol for 20 min.  (a) MAP-1 
associated with microtubules  in the freshly lysed cell: (b) MAP-1 
is only associated with perinuclear fibers after exposure of  the same 
cell to 60 laM estramustine for 30 min at 37°C; (c) the microtubules 
are intact after 30 min exposure to the 60 }.tM estramustine.  Anti- 
body staining was carried out by adding MAP-1 antibody plus sec- 
ondary antibody (1:400 dilution) to the lysis buffer for 30 min at 
37°C  followed by three  washes  with  PBS. The cell  was photo- 
graphed (a) and exposed to 60 ~tM estramustine for 30 min at 37°C, 
then fixed and stained with tubulin antibody  (1:100 dilution)  and 
RITC IgG (1:400) for rephotographing  (b and c).  Bar, 10 I.tm. 
cultured fibroblasts (Kotani et al.,  1987). We have identified 
similar 205- and a  190-kD MAPs associated with microtu- 
bules isolated from DU  145 cells (unpublished data) using 
the assembly-disassembly protocols of Murphy and Borisy 
(1975).  At this time, we have not determined if these MAPs 
can bind estramustine or if drug interaction with the 205- or 
190-kD MAPs also affects microtubule stability. 
Earlier studies in our laboratory revealed that estramustine 
binds pig brain MAP-1 and -2 to inhibit microtubule assem- 
bly and prevent MAP-1  and -2 binding 6S  "taxol microtu- 
bules" (Stearns and Tew,  1988; Tew and Stearns,  1988).  In 
addition,  estramustine inhibited purified MAP-2's microtu- 
bule assembly-promoting activities.  Initial kinetic binding 
studies showed that [3H]estramustine binds purified MAP-2 
with a  Kd  =  15  p.M.  Bmax calculations revealed that  "~20 
molecules of estramustine bind each molecule of MAP-2. 
Likewise, preliminary binding studies showed saturation of 
estramustine binding sites on the purified DU  145  330-kD 
protein. Scatchard and nonlinear regression analysis gave a 
K~ of "~10 IxM, and saturation occurred at 15 molecules of 
estramustine for each 330-kD molecule (data not  shown). 
Under the physiological parameters for microtubule assem- 
bly, excess amounts of estramustine (,x,60 IxM) were required 
to inhibit MAP-2's activities (e.g., at concentrations of 0.2 
mg MAP-2 and 2 mg/ml 6S tubulin).  This requirement for 
excess drug was identical to that observed for estramustine- 
MAP-1  interactions. 
Continued studies with estramustine should help unravel 
critical  problems in  microtubule biology concerning  how 
distinct microtubules are differentially assembled and disas- 
sembled. The process is complex as it involves MAPs, tubu- 
lin, and nucleotide interactions. Of considerable interest are 
the mechanisms and kinetics of tubulin addition (or loss) to 
the microtubule ends since MAPs are thought to assemble 
with tubulin and stabilize the elongating microtubules (Murphy 
et al., 1977). Likewise, the role(s) of MAPs in motility, cyto- 
plasmic transport, secretion, and cell morphogenesis might 
be delineated using estramustine. 
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